CHGA and neoplasm: Sandostatin was given to minimize risks associated with serotonin release from the PNET during portal vein stenting procedures, and therefore, active serotonin and chromogranin A release from the tumor into the TDV1 during sampling is expected to be minimal and could explain the lack of enrichment in the TDV1 during sampling (41).